Skip to main content
SpringerLink
Log in

Bioavailability of a pediatric amlodipine suspension

  • Original Article
  • Published:
Pediatric Nephrology Aims and scope Submit manuscript

Abstract

Currently, a suspension of crushed tablets of amlodidpine is widely used in children with hypertension without knowledge of its bioavailability. A comparative bioavailability study of a tablet and suspension formulation of amlodipine was completed in 20 healthy adult volunteers. Bioequivalence of the suspension was not different from the tablets. These results support the use of the suspension in children who cannot take the tablet.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Pfammatter JP, Clericetti-Affolter C, Truttmann AC, Busch K, Laux-End R, Bianchetti MG (1998) Amlodipine once daily in systemic hypertension. Eur J Pediatr 157:618–621

    Article  CAS  PubMed  Google Scholar 

  2. Khattak S, Rogan JW, Saunders EF, Theis JG, Arbus GS, Koren G (1998) Efficacy of amlodipine in pediatric bone marrow transplant patients. Clin Pediatr (Phila) 37:31–35

    Google Scholar 

  3. Silverstein DM, Palmer J, Baluarte HJ, Brass C, Conley SB, Polinsky MS (1999) Use of calcium-channel blockers in pediatric renal transplant recipients. Pediatr Transplant 3:288–292

    Article  CAS  PubMed  Google Scholar 

  4. Tallian KB, Nahata MC, Turman MA, Mahan JD, Hayes JR, Menster MI (1999) Efficacy of amlodipine in pediatric patients with hypertension. Pediatr Nephrol 13:304–310

    Article  CAS  PubMed  Google Scholar 

  5. Flynn JT, Smoyer WE, Bunchman TE (2000) Treatment of hypertensive children with amlodipine. Am J Hypertens 13:1061–1066

    CAS  PubMed  Google Scholar 

  6. Rogan JW, Lyszkiewicz DA, Blowey D, Khattak S, Arbus GS, Koren G (2000) A randomized prospective crossover trial of amlodipine in pediatric hypertension. Pediatr Nephrol 14:1083–1087

    Article  CAS  PubMed  Google Scholar 

  7. vonVigier RO, Franscini LM, Bianda ND, Pfister R, Casaulta Aebischer C, Bianchetti MG (2001) Antihypertensive efficacy of amlodipine in children with chronic kidney diseases. J Hum Hypertens 15:387–391

    Article  CAS  PubMed  Google Scholar 

  8. Temple ME, Nahata MC (2000) Treatment of pediatric hypertension. Pharmacotherapy 20:140–150

    CAS  PubMed  Google Scholar 

  9. Nahata MC, Morosco RS, Hipple TF (1999) Stability of amlodipine besylate in two liquid dosage forms. J Am Pharm Assoc 39:375–377

    CAS  Google Scholar 

  10. Meyer MC (2001) United States Food and Drug Administration requirements for approval of generic drug products. J Clin Psychiatry 62 [Suppl] 5:4–9

    Google Scholar 

  11. Drugs Directorate Guidelines (1992) Conduct and analysis of bioavailability and bioequivalence studies. A. Oral dosage formulations used for systemic effects. Therapeutic Products Directorate, Health Canada

  12. Rippley RK, Conner J, Bradstreet TE, Hand E, Lo MW, Murphy MG (2000) Pharmacokinetic assessment of an oral enalapril suspension for use in children. Biopharm Drug Disops 21:339–344

    Article  CAS  Google Scholar 

  13. Smith AL, Meeks CA, Koup JR, Opheim KE, Weber A, Vishwanathar CT (1990) Dicloxacillin absorption and elimination in children. Dev Pharmacol Ther 14:35–44

    CAS  PubMed  Google Scholar 

  14. Faulkner JK, Hayden ML, Chasseaud LF, Taylor T (1989) Absorption of amlodipine unaffected by food. Solid dose equivalent to solution dose. Arzneimittelforschung 39:799–801

    CAS  PubMed  Google Scholar 

Download references

Acknowledgements

Measurements of amlodipine were financially supported by Pfizer Central Research. Supported in part by a grant from the Canadian Institute for Health Research. G.K. is a Senior Scientist of the Canadian Institute for Health Research. E.K. was and MH is recipient of training grants from The Hospital for Sick Children Research Training Center.

Author information

Authors and Affiliations

  1. Division of Clinical Pharmacology and Toxicology, Hospital for Sick Children, 555 University Avenue, Toronto, Ontario, Canada

    Dorothy A. Lyszkiewicz, Zina Levichek, Eran Kozer, Yaron Yagev, Myla Moretti, Marjie Hard & Gideon Koren

Authors
  1. Dorothy A. Lyszkiewicz
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Zina Levichek
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Eran Kozer
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Yaron Yagev
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Myla Moretti
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Marjie Hard
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Gideon Koren
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Gideon Koren.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Lyszkiewicz, D.A., Levichek, Z., Kozer, E. et al. Bioavailability of a pediatric amlodipine suspension. Pediatr Nephrol 18, 675–678 (2003). https://doi.org/10.1007/s00467-003-1088-2

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00467-003-1088-2

Keywords

Search

Navigation